News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,598 Results
Type
Article (14195)
Company Profile (282)
Press Release (252121)
Section
Business (79501)
Career Advice (153)
Deals (13225)
Drug Delivery (35)
Drug Development (50444)
Employer Resources (31)
FDA (5715)
Job Trends (5127)
News (144381)
Policy (10028)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (910)
Accelerated approval (2)
Adcomms (12)
Allergies (49)
Alliances (21635)
ALS (61)
Alzheimer's disease (826)
Antibody-drug conjugate (ADC) (87)
Approvals (5730)
Artificial intelligence (108)
Autoimmune disease (11)
Automation (5)
Bankruptcy (104)
Best Places to Work (4560)
BIOSECURE Act (5)
Biosimilars (40)
Biotechnology (232)
Bladder cancer (45)
Brain cancer (19)
Breast cancer (141)
Cancer (1306)
Cardiovascular disease (110)
Career advice (132)
Career pathing (2)
CAR-T (107)
Cell therapy (307)
Cervical cancer (8)
Clinical research (40895)
Collaboration (497)
Compensation (219)
Complete response letters (13)
COVID-19 (1034)
CRISPR (37)
C-suite (146)
Cystic fibrosis (76)
Data (1362)
Denatured (11)
Depression (29)
Diabetes (126)
Diagnostics (1292)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (77)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (82)
Earnings (29682)
Editorial (17)
Employer branding (4)
Employer resources (29)
Events (48138)
Executive appointments (403)
FDA (6336)
Featured Employer (31)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (466)
Gene editing (89)
Generative AI (9)
Gene therapy (231)
GLP-1 (357)
Government (1074)
Grass and pollen (2)
Guidances (18)
Healthcare (6590)
Huntington's disease (21)
IgA nephropathy (21)
Immunology and inflammation (80)
Indications (18)
Infectious disease (1096)
Inflammatory bowel disease (110)
Inflation Reduction Act (8)
Influenza (18)
Intellectual property (57)
Interviews (17)
IPO (7261)
IRA (11)
Job creations (860)
Job search strategy (127)
Kidney cancer (6)
Labor market (4)
Layoffs (202)
Leadership (2)
Legal (1386)
Liver cancer (30)
Lung cancer (186)
Lymphoma (84)
Machine learning (1)
Management (7)
Manufacturing (115)
MASH (48)
Medical device (2588)
Medtech (2589)
Mergers & acquisitions (6252)
Metabolic disorders (364)
Multiple sclerosis (51)
NASH (13)
Neurodegenerative disease (57)
Neuropsychiatric disorders (23)
Neuroscience (1195)
NextGen: Class of 2025 (2017)
Non-profit (852)
Northern California (1553)
Now hiring (21)
Obesity (185)
Opinion (100)
Ovarian cancer (60)
Pain (40)
Pancreatic cancer (51)
Parkinson's disease (105)
Partnered (8)
Patents (111)
Patient recruitment (66)
Peanut (35)
People (25506)
Pharmaceutical (48)
Pharmacy benefit managers (5)
Phase I (14440)
Phase II (19026)
Phase III (12033)
Pipeline (726)
Podcasts (46)
Policy (37)
Postmarket research (852)
Preclinical (6062)
Press Release (30)
Prostate cancer (55)
Psychedelics (35)
Radiopharmaceuticals (212)
Rare diseases (274)
Real estate (1414)
Recruiting (12)
Regulatory (8565)
Reports (15)
Research institute (937)
Resumes & cover letters (17)
Rett syndrome (3)
RNA editing (4)
RSV (10)
Schizophrenia (56)
Series A (91)
Series B (60)
Service/supplier (1)
Sickle cell disease (38)
Southern California (1379)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (11)
Startups (1971)
State (1)
Stomach cancer (4)
Supply chain (18)
The Weekly (33)
United States (12140)
Vaccines (205)
Venture capitalists (28)
Webinars (7)
Weight loss (105)
Women's health (15)
Worklife (2)
Date
Today (150)
Last 7 days (445)
Last 30 days (1660)
Last 365 days (20056)
2025 (4775)
2024 (20552)
2023 (22414)
2022 (26822)
2021 (27806)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (148)
Alabama (38)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17221)
Australia (2917)
California (3530)
Canada (1051)
China (324)
Colorado (136)
Connecticut (143)
Delaware (88)
Europe (37027)
Florida (414)
Georgia (108)
Idaho (16)
Illinois (211)
India (8)
Indiana (85)
Iowa (1)
Japan (71)
Kansas (59)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (442)
Massachusetts (2785)
Michigan (69)
Minnesota (136)
Mississippi (1)
Missouri (22)
Montana (14)
Nebraska (4)
Nevada (15)
New Hampshire (14)
New Jersey (885)
New Mexico (12)
New York (957)
North Carolina (520)
North Dakota (4)
Northern California (1553)
Ohio (107)
Oklahoma (9)
Oregon (21)
Pennsylvania (675)
Puerto Rico (3)
Rhode Island (15)
South America (208)
South Carolina (4)
Southern California (1379)
Tennessee (25)
Texas (408)
Utah (48)
Virginia (68)
Washington D.C. (28)
Washington State (321)
Wisconsin (13)
266,598 Results for "iteos therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cancer
Cancer Pipelines Shrink as Incyte, iTeos Cut Candidates Following Disappointing Data
Incyte is abandoning its ALK2 blocker zilurgisertib, which it was trialing for myelofibrosis-associated anemia, while iTeos will deprioritize the development of inupadenant after it failed to meet the biotech’s clinical bar in a Phase II study of metastatic non-small cell lung cancer.
December 13, 2024
·
2 min read
·
Tristan Manalac
Press Releases
iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
March 5, 2025
·
11 min read
Press Releases
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones
January 13, 2025
·
9 min read
Genetown
iTeos Therapeutics Announces $120 Million Registered Direct Offering
iTeos Therapeutics, Inc. announced that it has entered into a securities purchase agreement to sell 1,142,857 shares of the Company’s common stock at a price of $17.50 per share, representing a premium of approximately 44% to iTeos’ closing price on May 9, 2024 and pre-funded warrants to purchase up to 5,714,285 shares of the Common Stock at a price of $17.499 per pre-funded warrant, in a registered direct offering.
May 10, 2024
·
6 min read
Lung cancer
GSK, iTeos Score Phase II Win for Jemperli-TIGIT Combo in NSCLC
High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light for anti-TIGIT therapies after a string of failures.
September 16, 2024
·
2 min read
·
Tristan Manalac
Press Releases
iTeos to Participate in Upcoming Investor Conferences
November 26, 2024
·
1 min read
Press Releases
iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 9, 2025
·
1 min read
Press Releases
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025
March 25, 2025
·
4 min read
Cancer
TIGITs Trend Upward After iTeos/GSK Present Positive Data at ESMO
After several high-profile failures, including BMS’ $1.5B breakup with Agenus, anti-TIGIT therapies are generating cautious optimism.
October 7, 2024
·
6 min read
·
Gail Dutton
Press Releases
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
December 12, 2024
·
9 min read
1 of 26,660
Next